Nimesulida Basi (Nimesulide)

Nimesulide selectively blocks the cyclooxygenase‑2 (COX‑2) enzyme, reducing the synthesis of prostaglandins that mediate inflammation, pain, and fever. By sparing COX‑1 activity, it aims to maintain gastric protection while delivering its therapeutic effect.

The exact dosage of Nimesulida Basi is determined by the prescribing clinician based on the patient’s condition, age, renal and hepatic function, and other individual factors. Healthcare professionals follow local prescribing guidelines to set the appropriate regimen.

Safety data for nimesulide in pregnancy and lactation are limited, and the product is generally avoided unless the potential benefit justifies the potential risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Nimesulida Basi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nimesulide is a selective COX‑2 inhibitor, which may offer a lower risk of gastrointestinal irritation compared with non‑selective NSAIDs such as ibuprofen or diclofenac. However, it carries its own hepatic safety considerations, so clinicians balance efficacy, safety profile, and patient history when choosing therapy.

Nimesulida Basi should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperatures to maintain its stability and potency throughout its shelf life.

The medication is taken orally, usually with a full glass of water. It can be taken with or without food, but patients should follow the prescribing clinician’s instructions regarding timing and whether to take it with meals to minimize gastrointestinal discomfort.

The most serious adverse events include severe liver injury (hepatitis, hepatic failure) and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Prompt medical attention is required if signs of liver dysfunction or severe skin rash develop.

Patients with known hypersensitivity to nimesulide or other NSAIDs, active liver disease, severe renal impairment, or a history of serious cardiovascular events should avoid Nimesulida Basi. It is also contraindicated in individuals taking certain anticoagulants or other COX‑2 inhibitors without medical supervision.